EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

Gabriele Roccuzzo, Eleonora Bongiovanni, Giovanni Actis-Giorgetto, Chiara Astrua, Matteo Giovanni Brizio, Giovanni Cavaliere, Paolo Fava, Simone Ribero, Pietro Quaglino

Frontiers in Pharmacology · 06.03.2026 · 17

DOI: 10.3389/fphar.2026.1601650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.03.2026. Verfasst von Gabriele Roccuzzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer with increasing incidence. The anti-PD-1 therapy cemiplimab has shown its antitumor activity in locally advanced (lacSCC) and metastatic cSCC (mcSCC). This retrospective study assessed the real-life effectiveness and safety of cemiplimab in 83 patients with lacSCC (n = 53) and mcSCC (n = 30). The objective response rate (ORR) was 49.4%, with a complete response (CR) in 15.7% and a partial response (PR) in 33.7%. The median progression-free survival (PFS) was 14 months (95% CI 9–55) and the median overall survival (OS) 19 months (95% CI 10–39). Half of patients (50.6%) experienced adverse events (AE) of any grade, with 8.4% discontinuing therapy due to the severe AEs. The subset of patients who experienced progression during therapy displayed younger age (p = 0.002), a higher disease stage at baseline (p = 0.003), and a nodal disease (p = 0.041). No differences in survival outcome emerged between patients with nodal vs. distant metastases, previous radiotherapy recipient vs. radiotherapy-naïve, and immunosuppressed vs. immunocompetent patients. Head&neck tumor site was associated with a longer OS after first progression (OS2, HR 0.29, 95% CI 0.09–0.89). This study supports the safe and effective use of cemiplimab in real life clinical practice yet highlights the need for further identification of new predictors of clinical response.

Schlagwörter

Stichwörter der Autor:innen

PD-1 inhibitorscemiplimabcheckpoint inhibitor therapycutaneous squamous cell carcinomaimmunosuppressionreal-life

Autor:innen und Institutionen

  • Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.

Zitieren

APA

Roccuzzo, G., Bongiovanni, E., Actis-Giorgetto, G., Astrua, C., Brizio, M. G., Cavaliere, G., Fava, P., Ribero, S., & Quaglino, P. (2026). Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1601650

Vancouver

Roccuzzo G, Bongiovanni E, Actis-Giorgetto G, Astrua C, Brizio MG, Cavaliere G, et al. Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1601650

BibTeX
@article{Roccuzzo2026,
  author = {Roccuzzo, Gabriele and Bongiovanni, Eleonora and Actis-Giorgetto, Giovanni and Astrua, Chiara and Brizio, Matteo Giovanni and Cavaliere, Giovanni and Fava, Paolo and Ribero, Simone and Quaglino, Pietro},
  title = {Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1601650}
}
Kostenlos starten →